Patent ID: 7285574

Claim:
A method of inhibiting neural cell swelling in a subject having traumatic brain injury or cerebral ischemia, said method comprising administering to the subject a formulation comprising an effective amount of: a sulfonylurea receptor 1 (SUR1) antagonist that reduces the activity of a NC Ca-ATP channel; and a pharmaceutically acceptable carrier, wherein the NC Ca-ATP channel has the following characteristics: 1) it is a non-selective monovalent cation channel; 2) it is activated by an increase in intracellular calcium or by a decrease in intracellular ATP, or both; and 3) it is regulated by a SUR1, wherein said SUR1 antagonist is a compound that inhibits the activation or action of SUR1 and wherein said antagonist is selected from the group consisting of glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, gliclazide, glimepiride, and combinations thereof.